Aspire BioPharma, Inc. Net Assets
Aspire BioPharma, Inc. net assets. Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has net assets worth $11.76 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.54 Million) and total liabilities ($1.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Aspire BioPharma, Inc. (ASBP) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.76 Million |
| % of Total Assets | 86.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.32 |
Net Assets of Aspire BioPharma, Inc. (2021–2025)
Net assets of Aspire BioPharma, Inc. from 2021 to 2025. This chart illustrates how Aspire BioPharma, Inc.'s net assets have evolved over time, based on quarterly financial data. See ASBP equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual net assets of Aspire BioPharma, Inc. from 2021 to 2025. For live market cap and overall valuation, see Aspire BioPharma, Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-6.38 Million | -314.02% |
| 2024-12-31 | $-1.54 Million | -107.87% |
| 2023-12-31 | $19.58 Million | -93.23% |
| 2022-12-31 | $289.07 Million | +60856138.32% |
| 2021-12-31 | $-475.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aspire BioPharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2723260600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Aspire BioPharma, Inc. Net Assets Breakdown (December 2025)
Aspire BioPharma, Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $353.00 | % |
| Other Components | $20.88 Million | % |
| Total Equity | $-6.38 Million | 100.00% |
Aspire BioPharma, Inc. Competitors by Market Cap
The table below lists competitors of Aspire BioPharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gold Springs Resource Corp
TO:GRC
|
$10.24 Million |
|
Bitcoin Well Inc
V:BTCW
|
$10.25 Million |
|
CodeLab Capital A/S
OL:CODE
|
$10.25 Million |
|
Green Circle Decarbonize Technology Limited
NYSE MKT:GCDT
|
$10.25 Million |
|
E-H.(CH)ENT. H. DL-00001
F:1VC
|
$10.22 Million |
|
Phio Pharmaceuticals Corp
NASDAQ:PHIO
|
$10.22 Million |
|
O.R.T.
TA:ORTC
|
$10.22 Million |
|
Condor Energy Ltd
AU:CND
|
$10.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aspire BioPharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,540,088 to -6,376,329, a change of -4,836,241.
- Net loss of 24,480,848 reduced equity.
- New share issuances of 265,827 increased equity.
- Other factors increased equity by 19,378,780.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.48 Million | -383.93% |
| Share Issuances | $265.83K | +4.17% |
| Other Changes | $19.38 Million | +303.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aspire BioPharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $7.30 | x |
| 2022-12-31 | $321.74 | $7.30 | x |
| 2023-12-31 | $40.83 | $7.30 | x |
| 2024-12-31 | $-40.17 | $7.30 | x |
| 2025-12-31 | $-4.27 | $7.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aspire BioPharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -394725.06%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (4.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.43K |
| 2022 | 1.16% | 0.00% | 0.00x | 1.04x | $-25.57 Million |
| 2023 | 22.80% | 0.00% | 0.00x | 1.02x | $2.51 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.16 Million |
| 2025 | 0.00% | -394725.06% | 0.00x | 0.00x | $-23.84 Million |
Industry Comparison
This section compares Aspire BioPharma, Inc.'s net assets metrics with peer companies in the Auto Parts industry.
Industry Context
- Industry: Auto Parts
- Average net assets among peers: $1,787,079,444
- Average return on equity (ROE) among peers: 8.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aspire BioPharma, Inc. (ASBP) | $11.76 Million | 0.00% | 0.15x | $10.24 Million |
| Advance Auto Parts Inc (AAP) | $2.60 Billion | 17.87% | 3.61x | $2.89 Billion |
| Adient PLC (ADNT) | $2.76 Billion | -60.96% | 2.96x | $1.37 Billion |
| Allison Transmission Holdings Inc (ALSN) | $1.87 Billion | 33.37% | 2.26x | $9.38 Billion |
| Autoliv Inc (ALV) | $2.57 Billion | 18.99% | 2.24x | $8.96 Billion |
| Aptiv PLC (APTV) | $3.67 Billion | 29.07% | 2.40x | $9.18 Billion |
| Atmus Filtration Technologies Inc. (ATMU) | $447.60 Million | 31.90% | 0.76x | $3.48 Billion |
| American Axle & Manufacturing (AXL) | $604.90 Million | -5.55% | 7.85x | $1.36 Billion |
| AutoZone Inc (AZO) | $-877.98 Million | 0.00% | 0.00x | $47.07 Billion |
| BorgWarner Inc (BWA) | $2.44 Billion | 11.83% | 1.03x | $10.61 Billion |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more